Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Trial Design Update • Phase 2Trial update Wed, May 20, 2026, 7:00 AM EDT
Company profile
Skye Bioscience, Inc.
Pipeline1 asset
- NimacimabCB1 / Monoclonal antibody / Metabolic DiseasesObesityPhase 2activeUnited States
Latest news12 items
All newsUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Trial Design Update • Phase 2Cohort Review Committee review Mon, May 18, 2026, 1:33 PM EDT
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Trial Start • Phase 2